Literature DB >> 2837318

Effect of O6-methylguanine on DNA interstrand cross-link formation by chloroethylnitrosoureas and 2-chloroethyl(methylsulfonyl)methanesulfonate.

M E Dolan1, A E Pegg, N K Hora, L C Erickson.   

Abstract

Exposure of HT29 cells in culture to O6-methylguanine is known to result in a reduction in O6-alkylguanine-DNA alkyltransferase (AGT) activity and an enhancement of sensitivity to the cytotoxic effects of chloroethylating agents. Since cytotoxicity of these agents may be mediated by the formation of interstrand cross-links, alkaline elution analysis was performed on HT29 cells treated with 1-(2-chloroethyl)-1-nitrosourea, 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea, and Clomesone [2-chloroethyl(methylsulfonyl)methanesulfonate] in the presence or absence of O6-methylguanine pretreatment to determine if the enhanced toxicity was due to an increase in the number of cross-links formed. Interstrand cross-linking by 1-(2-chloroethyl)-1-nitrosourea or 1-(2-chloroethyl)-3-cyclohexyl-1-nitrosourea was increased by pretreatment with 0.4 mM O6-methylguanine for 24 h. Cross-linking by Clomesone was observed only in cells exposed to 0.4 mM O6-methylguanine for 24 h prior to administration of the drug and for 12 h after administration, suggesting that the resynthesis of the AGT may prevent the cross-linking by Clomesone. Complete recovery of AGT activity after reduction to 20 to 30% of the basal level upon treatment with 0.4 mM O6-methylguanine required between 8 h and 15 h in both HT29 cells and in Raji cells which were also sensitized to 1-(2-chloro-ethyl)-3-cyclohexyl-1-nitrosourea by exposure to O6-methylguanine. These data suggest that the enhancement of chloroethylnitrosourea toxicity after treatment with O6-methylguanine may be related to an increase in the number of DNA cross-links and that the relatively rapid rate of AGT recovery plays a role in prevention of cross-links resulting from Clomesone.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 2837318

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  7 in total

1.  Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents.

Authors:  M E Dolan; R C Moschel; A E Pegg
Journal:  Proc Natl Acad Sci U S A       Date:  1990-07       Impact factor: 11.205

2.  Depletion of O6-alkylguanine-DNA alkyltransferase activity in mammalian tissues and human tumor xenografts in nude mice by treatment with O6-methylguanine.

Authors:  M E Dolan; G L Larkin; H F English; A E Pegg
Journal:  Cancer Chemother Pharmacol       Date:  1989       Impact factor: 3.333

3.  Treatment of subcutaneous and intracranial brain tumor xenografts with O6-benzylguanine and 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  G M Felker; H S Friedman; M E Dolan; R C Moschel; C Schold
Journal:  Cancer Chemother Pharmacol       Date:  1993       Impact factor: 3.333

4.  Potential of O6-methylguanine or O6-benzylguanine in the enhancement of chloroethylnitrosourea cytotoxicity on brain tumours.

Authors:  K Mineura; I Izumi; K Watanabe; M Kowada; K Kohda; M Ikenaga
Journal:  Acta Neurochir (Wien)       Date:  1994       Impact factor: 2.216

5.  Enhancement of ACNU cytotoxicity by pretreatment with O6-methylguanine in ACNU-resistant brain tumors.

Authors:  K Mineura; I Izumi; K Watanabe; M Kowada
Journal:  J Neurooncol       Date:  1994       Impact factor: 4.130

6.  RBPJ-dependent Notch signaling initiates the T cell program in a subset of thymus-seeding progenitors.

Authors:  Edward L Y Chen; Patrycja K Thompson; Juan Carlos Zúñiga-Pflücker
Journal:  Nat Immunol       Date:  2019-10-21       Impact factor: 25.606

7.  Potentiation of temozolomide and BCNU cytotoxicity by O(6)-benzylguanine: a comparative study in vitro.

Authors:  S R Wedge; J K Porteus; B L May; E S Newlands
Journal:  Br J Cancer       Date:  1996-02       Impact factor: 7.640

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.